Glenmark launched affordable Type 2 diabetes drug Teneligliptin
Teneligliptin introduced under the brand names Ziten and Zita Plus is effective in suppressing glucagon release and increasing insulin to subsequently lower blood glucose levels.
Glenmark Pharmaceuticals Limited on 22 July 2015 launched the affordable third-generation oral anti-diabetic drug Teneligliptin for treatment of Type-2 Diabetes mellitus. The company introduced Teneligliptin under the brand names Ziten and Zita Plus.
The drugs have been priced at 19.90 rupees per tablet and will be enough for a day's treatment. It is claimed to be 55 percent cheaper than other drugs in the market.
The drug is effective in suppressing glucagon release and increasing insulin to subsequently lower blood glucose levels.
Although many other firms such as USV and Sun Pharma sell gliptins but Glenmark is the first Indian company to introduce the molecule after clinical trials and approval from the Drug Controller General of India (DCGI) for exclusive sale in India.
According to International Diabetes Federation's (IDF) metrics, there were 66.8 million diabetes patients in India in 2014 which will rise to 110 million patients by 2035.
Further, the entire diabetes treatment market of India is valued at 6600 crore rupees.
Glenmark Pharmaceuticals is an Indian pharmaceutical company based in Mumbai. It was founded in 1977 by Gracias Saldanha.
Now get latest Current Affairs on mobile, Download # 1 Current Affairs App